SCHEMBL29670786

SCHEMBL29670786

CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
PTGS2 P35354 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SLC7A5 Q01650 1/20 0.46
ECE1 P42892 1/20 0.41
OPRD1 P41143 8/20 0.40
OPRM1 P35372 5/20 0.40
OPRK1 P41145 2/20 0.40
LARS1 Q9P2J5 1/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
ANPEP P15144 2/20 0.39
RNPEP Q9H4A4 2/20 0.39
DNPEP Q9ULA0 1/20 0.39
MMP8 P22894 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31064905 0.98 ALDH1A1 (0.44) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29723604 0.91 BACE1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30099503 0.91 OPRD1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL31258959 0.88 MME (0.44) MMEACECPA1ACE2
SCHEMBL620370 0.88 SLC7A5 (0.54) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL620369 0.88 SLC7A5 (0.54) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL6047667 0.88 SLC7A5 (0.54) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL11788108 0.87 SLC7A5 (0.41) SLC7A5OPRD1OPRM1OPRK1LARS1
SCHEMBL11788120 0.87 SLC7A5 (0.41) SLC7A5OPRD1OPRM1OPRK1LARS1
SCHEMBL11664472 0.86 ALDH1A1 (0.40) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114958797-A Mutant DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof 郑州思昆生物工程有限公司 2022-08-30 CN claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
CN-114958797-B Mutant DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof 郑州思昆生物工程有限公司 2025-03-25 CN disclosed
CN-119490563-A Bird's nest peptide for promoting silk fibroin and inhibiting expression of inflammatory factors 厦门市燕之屋丝浓生物科技有限公司 2025-02-21 CN disclosed
CN-119390781-A Polypeptide specifically binding to Nectin-4 and application thereof 湖南中晟全肽生物科技股份有限公司 2025-02-07 CN disclosed
CN-119345324-A Structure and application of bird's nest monopeptide for enhancing and improving lung function and preventing pulmonary fibrosis 厦门市燕之屋丝浓生物科技有限公司 2025-01-24 CN disclosed
CN-119119249-A Binding protein comprising AAV-9 antigen binding domain 杭州艾策生物技术有限公司 2024-12-13 CN disclosed
CN-118853640-A Carbapenem drug-resistant gene and application thereof 郑州大学 2024-10-29 CN disclosed
US-20240299562-A1 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY COBIORES NV (BE) 2024-09-12 US disclosed
US-20240123074-A1 MINIMALLY TOXIC PRODRUGS COBIORES NV (BE) 2024-04-18 US disclosed
US-11939369-B2 Integrin antagonists THE GENERAL HOSPITAL CORPORATION (US) 2024-03-26 US disclosed
EP-4267188-A1 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY Cobiores NV (BE) 2023-11-01 EP disclosed
CN-116635054-A Compounds comprising tetrapeptide moieties 科比欧尔斯公司 2023-08-22 CN disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
CN-114958797-A Mutant DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof 郑州思昆生物工程有限公司 2022-08-30 CN disclosed
WO-2022167664-A1 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY COBIORES NV (BE) 2022-08-11 WO disclosed
WO-2022136586-A1 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY COBIORES NV (BE) 2022-06-30 WO disclosed
US-20220153812-A1 INTEGRIN ANTAGONISTS THE GENERAL HOSPITAL CORPORATION 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939369-B2 Integrin antagonists ITGB3, ITGA2B, ITGB1 ALDH1A1 1940/4885LMNA 3167/4885MAPT 4662/4885
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP ALDH1A1 3596/4885LMNA 1538/4885MAPT 3330/4885
US-20240123074-A1 MINIMALLY TOXIC PRODRUGS ALG8, ALG1, LNPEP ALDH1A1 1676/4885LMNA 2409/4885MAPT 2710/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD ALDH1A1 4110/4885LMNA 3184/4885MAPT 4191/4885
US-20220153812-A1 INTEGRIN ANTAGONISTS ITGB3, ITGA2B, ITGB1 ALDH1A1 1940/4885LMNA 3167/4885MAPT 4662/4885
US-20240299562-A1 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY DNPEP, NPEPPS, ENPEP ALDH1A1 1998/4885LMNA 2734/4885MAPT 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.